Drugs / Ibudilast
Trials 18 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT04644003 | Dec 2020 → Jan 2022 | autism spectrum disorder | Stalicla SA | Completed | No outcome recorded |
| Phase 1 | NCT03533387 | Apr → Jul 2018 | — | MediciNova | Completed | No outcome recorded |
| Phase 1 | NCT02025998 | Dec 2013 → Jun 2015 | alcohol-related disorders | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 1 | NCT01389193 | Jun 2013 → Dec 2015 | migraine disorder | Parisa Gazerani | Completed | No outcome recorded |
| Phase 1 | NCT01217970 | Jan 2011 → Mar 2013 | methamphetamine dependence, substance abuse | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT03782415 | Dec 2018 → Aug 2023 | glioblastoma | MediciNova | Completed | No outcome recorded |
| Phase 1/2 | NCT02714036 | May 2016 → Dec 2019 | amyotrophic lateral sclerosis | MediciNova | Completed | No outcome recorded |
| Phase 1/2 | NCT01317992 | Apr 2011 → Jun 2013 | — | University of Adelaide | Unknown | No outcome recorded |
| Phase 1/2 | NCT00576277 | Sep 2006 → Nov 2007 | diabetic neuropathy | Avigen | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT04429555 | Jan 2021 → Jun 2022 | viral pneumonia | MediciNova | Completed | No outcome recorded |
| Phase 2 | NCT03594435 | Oct 2018 → Apr 2023 | alcohol-related disorders | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 2 | NCT02238626 | Sep 2014 → Aug 2017 | amyotrophic lateral sclerosis | MediciNova | Completed | No outcome recorded |
| Phase 2 | NCT01982942 | Nov 2013 → May 2017 | primary progressive multiple sclerosis, secondary progressive multiple sclerosis | MediciNova | Completed | No outcome recorded |
| Phase 2 | NCT01860807 | Jul 2013 → Dec 2017 | HIV infectious disease, methamphetamine dependence | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 2 | NCT00723177 | Oct 2008 → Apr 2010 | substance-related disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT05513560 | May 2023 → Mar 2025 | long COVID-19 | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 2/3 | NCT04057898 | May 2020 → Apr 2027 expected | amyotrophic lateral sclerosis | MediciNova | Active not recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT06743776 | — | amyotrophic lateral sclerosis | Mayo Clinic | Available | No outcome recorded |
Also used as a comparator or background therapy in 6 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04054206 Comparator | Jun → Jul 2019 | — | MediciNova | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT05414240 Comparator | Jan 2023 → Dec 2026 expected | alcohol dependence | University of Pennsylvania | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03341078 Comparator | May 2019 → Oct 2025 | methamphetamine dependence | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 2 | NCT03489850 Comparator | Jul 2018 → Mar 2020 | alcohol-related disorders | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 2 | NCT01740414 Comparator | Nov 2012 → Dec 2015 | opiate dependence, opioid abuse | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04631471 Comparator | Dec 2021 → Sep 2026 expected | spinal cord disorder | Cambridge University Hospitals NHS Foundation Trust | Recruiting | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 27 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ibudilast | “This study aimed to evaluate the safety and tolerability of STP1, a combination of ibudilast and bumetanide, tailored for the treatment of a clinically and biologically defined...” PMID 39062003 ↗ Jun 202416“Ibudilast (MN-166, formerly AV411) is a compound that inhibits the activation of glia.” NCT01740414 ↗ “MN-166 (ibudilast)” NCT06743776 ↗ |
| Known as | AV411 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00576277 ↗ |
| Known as | IBUD | “This study is a double-blind, placebo-controlled randomized clinical trial of Ibudilast (IBUD) (50mg twice a day) for the treatment of Alcohol Use Disorder (AUD).” NCT03594435 ↗3“Ibudilast (IBUD) is a macrophage migration inhibitory factor (MIF) and phosphodiesterase (PDE)-4 and -10 inhibitor at peak clinical exposures” NCT01860807 ↗ “Ibudilast (IBUD) is a neuroimmune modulator that inhibits phosphodiesterase-4 and -10 and macrophage migration inhibitory factor.” NCT03489850 ↗ “Ibudilast (IBUD) is a neuroimmune modulator that inhibits phosphodiesterase-4 and -10 and macrophage migration inhibitory factor.” PMID 29794557 ↗ Sep 2018 |
| Known as | ibudilast/AV411 | “ibudilast/AV411” NCT01740414 ↗ |
| Known as | Ketas | ChEMBL registry synonym — accepted as the source's own label CHEMBL19449 ↗ |
| Known as | MN-166 | “Ibudilast (MN-166, formerly AV411) is a compound that inhibits the activation of glia.” NCT01740414 ↗ |
| Action | Inhibit | “The Safety, Tolerability and Preliminary Efficacy of AV411, a Glial Activation Inhibitor, in Heroin Abusers Under Conditions of Morphine Maintenance and Withdrawal” NCT00723177 ↗3“Phosphodiesterase 10A inhibitor” CHEMBL19449 ↗ “Phosphodiesterase 5A inhibitor” CHEMBL19449 ↗ “Phosphodiesterase 3A inhibitor” CHEMBL19449 ↗ |
| Modality | Small molecule | “Ibudilast is a small molecule that crosses the blood-brain barrier after oral administration.” NCT02714036 ↗ |
| Route | Oral | “Low (20 mg), and high dose (40 mg) of AV411 will be administered orally twice a day (BID) for two consecutive weeks” NCT00723177 ↗ |
| Target | MIF | “Ibudilast (MN-166) is an inhibitor of macrophage migration inhibitory factor (MIF) and phosphodiesterases 3,4,10 and 11” PMID 34016561 ↗ Apr 2021 |
| Target | PDE10A | “Phosphodiesterase 10A inhibitor” CHEMBL19449 ↗ |
| Target | PDE3A | “Phosphodiesterase 3A inhibitor” CHEMBL19449 ↗ |
| Target | PDE5A | “Phosphodiesterase 5A inhibitor” CHEMBL19449 ↗ |